Navigation Links
Alma(TM) Lasers to Debut Five New Products at the 66th Annual Meeting of the American Academy of Dermatology
Date:2/1/2008

BUFFALO GROVE, Ill., Feb. 1 /PRNewswire/ -- Alma Lasers Ltd. ("Alma Lasers"), a global developer and marketer of laser, intense pulsed light, and radiofrequency-based aesthetic devices, announced today that it will unveil five new products at the 66th Annual Meeting of the American Academy of Dermatology (AAD) in San Antonio, Texas, from February 2nd to 4th. Company representatives will be available during this time to discuss Alma Lasers' full line of products in booth #4465 at the Henry B. Gonzalez Convention Center.

These new products include the Harmony(XL) Multi-Application System, Pixel CO2 OmniFit handpiece, Pixel Er OmniFit handpiece, Pixel CO2 System and Accent(XL) UniLarge handpiece. The Harmony(XL) has more power, five new contact-cooled handpieces, a high-powered Pixel(TM) 2940 for fractional ablative skin resurfacing, Pain-Free Hair Removal, and a LED handpiece for post-treatment erythema. The Harmony(XL) Multi-Application System's unique modularity and upgradeability allow users to enhance their aesthetic services as needed. It has a wide range of aesthetic and medical applications available in a single system, including Harmony(XL)'s Laser 360, a comprehensive skin rejuvenation treatment.

The Pixel CO2 OmniFit and the Pixel Er OmniFit handpiece converts nearly any competitive CO2 and erbium skin resurfacing laser to a fractionated output to provide shorter healing times with the performance of traditional CO2 and erbium treatments. The Pixel CO2 System is a stand-alone system that incorporates Alma's proprietary passive optic fractional technology to provide fractionated skin resurfacing for the treatment of acne scars, photo-damaged skin, wrinkles and rhytids.

The Accent(XL) UniLarge handpiece delivers UniPolar energy with a 45 percent larger tip size and 36 percent greater power to treat larger body parts faster. The Accent(XL) UniLarge handpiece is approved by FDA for the treatment of wrinkles and rhytids.

The Har
'/>"/>

SOURCE Alma Lasers Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Alma Lasers Announces Proposed Initial Public Offering
2. Alma Lasers Answers Lumenis Complaint
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Sense of personal control influences Latinas decisions about sexual debut
5. American Red Cross Partners With Safety4Kids(R) to Debut Childrens Fire Safety DVD
6. Synergy Life Science Partners Closes $143M Debut Medical Device Fund
7. A Whole New Sandwich Debuts in the Freezer Aisle: LEAN POCKETS(R) Brand Introduces Latest Whole Grain Varieties
8. Omnicell Debuts Industrys First Total Automated Patient-Specific Management Solution
9. Sneaky Chefs Recipes Make Delicious Debut at Morgan Stanley Childrens Hospital
10. Long Term Care Newsletter Debuts, Published by LTC Financial Partners; Advice on Living Better, Not Just Longer, With Financial Protection
11. Rutgers biomaterial debuts in clinical trials of new stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... BOSTON, Nov. 21 Innerscope Resea... firm specializing in Emotional Response Measureme...utives who will strengthen the,company,s research...,initiatives. , The three appointments, who...de Geoffrey Gill as Chief Financial Officer and Vi...
(Date:11/21/2008)... , COLD SPRING HARBOR, N.Y. (Nov. 21, 2008) Ho...What can the lamprey immune system tell us about e...ations help with efforts to conserve rare species?...duction, and hereditary diseases? Will studies of... , To answer these and other questions in biolog...
(Date:11/21/2008)... WASHINGTON, Nov. 21 New inventio... with a variety of cognitive disabilities lead ful...ience(R) Corporation. Zimman,presented today at t...ington,DC, a meeting organized by The National C...tion to assist people with disabilities. , ...
(Date:11/21/2008)... Winter viruses may be to blame, study suggests ...The season of a baby,s birth may help predict that..., Babies born in autumn -- about four months befo...a 30 percent increased risk of asthma compared to ...study in the first December issue of the American...
Breaking Medicine News(10 mins):Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:A new world of research possibilities with 'Emerging Model Organisms' 2Health News:New Applications for Cognitive Training 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3
...s of vitamin C notwithstanding, British researcher...! It is now said that vitamin C reverses pre eclam...e leading contributors to complications in childbi...n lead onto eclampsia which, when left untreated, ...
...hat causes infectious mononucleosis, Epstein-Barr ...o the development of Hodgkin's disease. But no one...BV and Hodgkin's survival, according to researcher... from Northern California Cancer Center in Union C...
...d on more than 1600 women reveals that parathyroid...ne density and cut the risk of fractures in them. ...ium levels in the body. The new aspect of th...ures has opened up the prospect of the hormone bei...
...n from Mayo Foundation in Rochester, Minnesota has...ble metal stents in the digestive tract of people ...ese patients commonly suffer from obstructions and...ke difficulty in swallowing, if the block is in th...
Other Medicine News:
(Date:11/20/2008)...- The Scandinavian-based drug,development company...on its,lead antimicrobial candidate LTX-109. Pres...wed that the novel lytic peptidomimetic has an ult...er towards killing Staphylococcus,aureus and Stre...gs. In,addition to this it has proven effective a...
(Date:11/19/2008)...significance , , ISELIN, N.J., Nov. 19 /PR...: PARS ) today announced results from its Phase ... drug delivery technology formulated with 3% Diclo... randomized, double-blinded, placebo-controlled st...ny,s 3% Diclofenac Diethanolamine NanoEmulsion cre...
(Date:11/19/2008)...a contract development and,manufacturing organiza...t,phase launch of its contract facility in Delawa...e process, facility and capacity problems commonly...w-volume clinical and,early-stage commercial ster... invest over $100 million and four years to develo...
(Date:11/18/2008)...make a donation or send a Christmas Seals e-card ,...re/ -- Millions will receive Christmas Seals in th...ssociation. These decorative holiday stamps are pa...to 1907 when the Lung Association led efforts to c...alive today have no vivid memories of how widespre...
Breaking Medicine Technology:Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Isogen Launches Major New Facility to Address Global Biopharma Demand 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Julia Zeitlinger named Pew Scholar 3651 1Julia Zeitlinger named Pew Scholar 3651 2INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 1INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 2AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 1AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 2Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide 28R 29 Tablets 21975 1
...ngress of European Hematology,Association (EHA) -,...all/ --,Immunomedics, Inc. , a biopharmaceutical c... to treat cancer and other serious,diseases, today...s,of EHA in Vienna, Austria, showed positive respo... treated with a new,radioimmunotherapy (RAIT) usin...
...ational Reserve" May Also Affect,Alzheimer,s Risk ...e/ -- A new study,suggests that treating risk fact...od pressure and diabetes, may slow the progression...orted today at the,2nd Alzheimer,s Association Int... Washington, DC. , Two new studies presented at th...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: